TD Cowen analyst Dan Brennan initiated coverage of Caris Life Sciences (CAI) with a Buy rating and $32 price target The firm sees additional share upside as it expects Caris to post “superior” sales growth and EBIT margin expansion. This should support a a premium multiple, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences
- Caris Life Sciences initiated with a Buy at Guggenheim
- Caris Life Sciences initiated with an Overweight at JPMorgan
- Caris Life Sciences initiated with a Buy at BofA
- Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating